

SUCCESS STORY




www.bioalberta.com

<https://providencetherapeutics.com>

Providence Therapeutics occupies a distinctive niche in the realm of mRNA vaccines. As a Canadian leader in this field, the company advances mRNA therapeutics and vaccines, positioning itself at the forefront of healthcare innovation. Its contributions to the development of mRNA-based treatments, coupled with its commitment to quality and safety, highlight its unique role in addressing medical challenges through cutting-edge biotechnology. The company's internship opportunities provide an exceptional experience for students to engage directly in this ground-breaking field.

Hiring students benefits Providence Therapeutics by infusing fresh perspectives, diverse skills, and energy into their day to day work. Students bring innovative ideas, contributions to projects, and offer a dynamic workforce. Internships establish a talent pipeline, identifying future professionals who can seamlessly transition into full-time roles and contribute to Providence's sustained growth while retaining home-grown talent in the province.

Kathy Zhan, a University of Calgary Chemical/Biomedical Engineering student, explains her interest in applying for an internship at Providence Therapeutics: "I have enjoyed classes related to biomedical engineering the most. For my undergraduate research project, I worked with a graduate student who was doing breast cancer research and that experience inspired me to pursue a career related to cancer diagnostics or therapeutics. I came upon a job posting for the position with Providence Therapeutics and the company's goals and aspirations really aligned with my own. I thought that the role would be the perfect opportunity." It appears this opportunity has worked out well for both parties, as Kathy played a pivotal role at



Kathy Zhan

Providence Therapeutics. She contributed to analytical assay development and routine testing, supporting the advancement of products in a new therapeutics portfolio. Collaborating internally, she also showcased adaptability by taking on diverse tasks. Kathy's active involvement and skill set significantly contributed to Providence's ongoing research and development efforts, advancing their mission in mRNA therapeutics and vaccines.

Kathy returns to her academics with experiences working with laboratory instruments and materials, writing technical documents, analyzing data, and a working knowledge of mRNA vaccine development. She leaves us with a final thought: "Being able to work in the field you are passionate about with many talented and knowledgeable individuals makes every day at work exciting."

WIL funding is a win-win for Providence Therapeutics:

"Work-Integrated Learning (WIL) funding significantly benefits Providence Therapeutics. It provides access to skilled student interns, infusing fresh skills and perspectives. Financial support aids in managing costs, allowing impactful learning experiences for both the company and the students. WIL funding accelerates projects aligned with our goals, fostering industry collaboration and knowledge exchange. This empowers us to nurture a skilled workforce, contribute to student education, and advance innovation in the biotech sector. Through WIL programs, we foster meaningful collaborations with aspiring talent, bridging the gap between education and real-world application. These interactions create a two-way street of learning, where our expertise meets fresh perspectives. This synergy not only propels our projects but also nurtures a sense of collective growth. Our journey at Providence Therapeutics revolves around constant growth and positive impact. We consistently seek opportunities, challenge norms, and respect diversity. Our commitment to honesty and responsibility shapes an environment where integrity thrives. Every member is empowered to take ownership of their actions, fostering a culture of accountability and achievement. Innovation is our compass, guiding us to craft unique solutions and stay at the forefront of mRNA-based therapeutics."

WIL VOUCHER

Alberta

bio
alberta
Association for Life Sciences Industry